Form D · Pharmaceuticals

Neuvivo, Inc.

Palo Alto, CA · CIK 0002154992

Offering snapshot reported Nov 13, 2026 · SEC filing

Reported sold
$1.38M
Offering amount: $9.5M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 30, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 13, 2026Initial$1,384,615No comparison1SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-604762

Source: Form D, filed Nov 13, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert Baffi Director
John Curnutte Director
Michael Mc Grath Director, Executive
Pornsit Poovanakijjakorn Director
Virit Vichitvadakan Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
2100 Geng Road Suite 210
Palo Alto, CA, 94303